Products
Pazopanib
Pharmacotherapeutic group
antitumor agent - proteintyrosine kinase inhibitorInternational name
PazopanibDosage form
film-coated tabletsProduct information
Download Pazopanib.pdf (RU)
Go to the State Register of Medicinal Products site ➞
Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor.
It inhibits many types of tyrosine kinases including vascular endothelial growth factor receptor-1, -2, and -3 (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptor-alpha and -beta (PDGFR-α and PDGFR-β) and Stem cell factor receptor (c-Kit) with IC50 values of 10, 30, 47, 71, 84 and 74 nM, respectively. In vitro, pazopanib inhibits ligand-induced auto-phosphorylation of VEGFR-2, c-Kit and PDGFR-ß receptors. In vivo, pazopanib inhibits VEGF-induced VEGFR-2 phosphorylation, angiogenesis, and the growth of multiple human tumour xenografts.